Multivariate regression for RFS and OS
| Variable . | n . | RFS . | OS . | ||||
|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | ||
| Observation | 94 | Ref | |||||
| AZA maintenance | 87 | 0.73 | 0.49-1.10 | .14 | 0.84 | 0.55-1.29 | .43 |
| AML | 134 | Ref | Ref | ||||
| MDS | 47 | 0.38 | 0.22-0.67 | <.001 | 0.39 | 0.22-0.71 | .002 |
| Cytogenetic risk groups | |||||||
| Good | 23 | Ref. | Ref | ||||
| Intermediate | 75 | 1.97 | 0.84-4.66 | .12 | 1.5 | 0.63-3.57 | .36 |
| Poor | 83 | 2.43 | 1.06-5.61 | .04 | 2.13 | 0.92-4.9 | .08 |
| Active disease | 115 | Ref | Ref | ||||
| Complete remission* | 66 | 0.48 | 0.3-0.75 | .001 | 0.53 | 0.33-0.84 | .007 |
| First allo-SCT | 166 | Ref | Ref. | ||||
| Second allo-SCT | 15 | 0.93 | 0.45-1.90 | .83 | 1.08 | 0.52-2.24 | .84 |
| Myeloablative conditioning | 149 | Ref | Ref | ||||
| Reduced intensity conditioning | 32 | 1.0 | 0.58-1.75 | .99 | 1.0 | 0.56-1.76 | .99 |
| Hematopoietic stem cell source | |||||||
| PBSC | 115 | Ref | Ref | ||||
| Cord blood unit | 3 | 3.72 | 0.95-14.62 | .06 | 7.59 | 1.81-31.8 | .006 |
| Bone marrow | 63 | 1.53 | 0.95-2.48 | .08 | 1.26 | 0.76-2.09 | .37 |
| HCT-CI <4 | 124 | Ref | Ref | ||||
| HCT-CI >3 | 57 | 1.37 | 0.9-2.09 | .14 | 1.44 | 0.93-2.24 | .10 |
| Variable . | n . | RFS . | OS . | ||||
|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | ||
| Observation | 94 | Ref | |||||
| AZA maintenance | 87 | 0.73 | 0.49-1.10 | .14 | 0.84 | 0.55-1.29 | .43 |
| AML | 134 | Ref | Ref | ||||
| MDS | 47 | 0.38 | 0.22-0.67 | <.001 | 0.39 | 0.22-0.71 | .002 |
| Cytogenetic risk groups | |||||||
| Good | 23 | Ref. | Ref | ||||
| Intermediate | 75 | 1.97 | 0.84-4.66 | .12 | 1.5 | 0.63-3.57 | .36 |
| Poor | 83 | 2.43 | 1.06-5.61 | .04 | 2.13 | 0.92-4.9 | .08 |
| Active disease | 115 | Ref | Ref | ||||
| Complete remission* | 66 | 0.48 | 0.3-0.75 | .001 | 0.53 | 0.33-0.84 | .007 |
| First allo-SCT | 166 | Ref | Ref. | ||||
| Second allo-SCT | 15 | 0.93 | 0.45-1.90 | .83 | 1.08 | 0.52-2.24 | .84 |
| Myeloablative conditioning | 149 | Ref | Ref | ||||
| Reduced intensity conditioning | 32 | 1.0 | 0.58-1.75 | .99 | 1.0 | 0.56-1.76 | .99 |
| Hematopoietic stem cell source | |||||||
| PBSC | 115 | Ref | Ref | ||||
| Cord blood unit | 3 | 3.72 | 0.95-14.62 | .06 | 7.59 | 1.81-31.8 | .006 |
| Bone marrow | 63 | 1.53 | 0.95-2.48 | .08 | 1.26 | 0.76-2.09 | .37 |
| HCT-CI <4 | 124 | Ref | Ref | ||||
| HCT-CI >3 | 57 | 1.37 | 0.9-2.09 | .14 | 1.44 | 0.93-2.24 | .10 |
Only patients in CR with count recovery were included in this group.